Time course of rocuronium-induced neuromuscular block after pre-treatment with magnesium sulphate: a randomised study

Acta Anaesthesiol Scand. 2010 Mar;54(3):299-306. doi: 10.1111/j.1399-6576.2009.02160.x. Epub 2009 Nov 16.

Abstract

Background: A previously published study suggested that pre-treatment with magnesium sulphate (MgSO(4)) had no impact on the speed of onset of rocuronium-induced neuromuscular block. We set out to verify this assumption.

Methods: Eighty patients (18-60 years) were randomly allocated to MgSO(4) 60 mg/kg or placebo (saline). Study drugs were given intravenously for 15 min before induction of anaesthesia with propofol, sufentanil and rocuronium 0.6 mg/kg. Anaesthesia was maintained with a target-controlled propofol infusion. Neuromuscular transmission was measured using train-of-four (TOF)-Watch SX acceleromyography.

Results: Onset was analysed in 37 MgSO(4) and 38 saline patients, and recovery in 35 MgSO(4) and 37 saline patients. Onset time (to 95% depression of T1) was on average 77 [SD=18] s with MgSO(4) and 120 [48] s with saline (P<0.001). The total recovery time (DurTOF0.9) was on average 73.2 [22] min with MgSO(4) and 57.8 [14.2] min with saline (P<0.003). The clinical duration (Dur25%) was on average 44.7 [14] min with MgSO(4) and 33.2 [8.1] min with saline (P<0.0002). The recovery index (Dur25-75%) was on average 14.0 [6] min with MgSO(4) and 11.2 [5.2] min with saline (P<0.02). The recovery time (Dur25%TOF0.9) was on average 28.5 [11.7] min with MgSO(4) and 24.7 [8.4] min with saline (P=0.28).

Conclusion: Magnesium sulphate given 15 min before propofol anaesthesia reduces the onset time of rocuronium by about 35% and prolongs the total recovery time by about 25%.

Trial registration: ClinicalTrials.gov NCT00405977.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adjuvants, Anesthesia* / adverse effects
  • Adolescent
  • Adult
  • Androstanols* / adverse effects
  • Anesthesia Recovery Period
  • Anesthesia, General
  • Data Interpretation, Statistical
  • Electric Stimulation
  • Endpoint Determination
  • Female
  • Humans
  • Injections, Intravenous
  • Magnesium Sulfate* / adverse effects
  • Male
  • Middle Aged
  • Myography
  • Neuromuscular Blockade* / adverse effects
  • Neuromuscular Nondepolarizing Agents* / adverse effects
  • Premedication
  • Rocuronium
  • Time Factors
  • Young Adult

Substances

  • Adjuvants, Anesthesia
  • Androstanols
  • Neuromuscular Nondepolarizing Agents
  • Magnesium Sulfate
  • Rocuronium

Associated data

  • ClinicalTrials.gov/NCT00405977